Giangregorio F. Capecitabine maintenance after radiofrequency ablation: A preventive strategy for lung oligometastases from colorectal cancer. World J Gastroenterol 2025; 31(48): 113550 [DOI: 10.3748/wjg.v31.i48.113550]
Corresponding Author of This Article
Francesco Giangregorio, MD, PhD, Associate Professor, Chief Physician, Director, Department of Internal Medicine, Castel San Giovanni Hospital, Viale II Giugno 1, Castel San Giovanni, Piacenza 29015, Emilia-Romagna, Italy. f.giangregorio67@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 28, 2025 (publication date) through Dec 27, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Giangregorio F. Capecitabine maintenance after radiofrequency ablation: A preventive strategy for lung oligometastases from colorectal cancer. World J Gastroenterol 2025; 31(48): 113550 [DOI: 10.3748/wjg.v31.i48.113550]
World J Gastroenterol. Dec 28, 2025; 31(48): 113550 Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113550
Capecitabine maintenance after radiofrequency ablation: A preventive strategy for lung oligometastases from colorectal cancer
Francesco Giangregorio
Francesco Giangregorio, Department of Internal Medicine, Castel San Giovanni Hospital, Piacenza 29015, Emilia-Romagna, Italy
Author contributions: Giangregorio F was responsible for the conception and design of the study, and the drafting of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Francesco Giangregorio, MD, PhD, Associate Professor, Chief Physician, Director, Department of Internal Medicine, Castel San Giovanni Hospital, Viale II Giugno 1, Castel San Giovanni, Piacenza 29015, Emilia-Romagna, Italy. f.giangregorio67@gmail.com
Received: August 28, 2025 Revised: October 11, 2025 Accepted: November 6, 2025 Published online: December 28, 2025 Processing time: 121 Days and 7.3 Hours
Abstract
Preventing the recurrence of lung oligometastases after local therapy in patients with colorectal cancer is an area requiring investigation. A recent article demonstrated that adding capecitabine maintenance therapy after radiofrequency ablation improved the 5-year overall survival (88.7% vs 69.1%) and reduced local tumor progression (22.7% vs 49.0%) compared with radiofrequency ablation alone. Although progression-free survival did not differ significantly between the two treatments, multivariate analysis confirmed a robust survival benefit. These findings support the use of systemic maintenance to eradicate micrometastases after locoregional control and warrant validation in prospective randomized trials.
Core Tip: Preventing the recurrence of lung oligometastases from colorectal cancer after local therapy is crucial. Recent evidence demonstrated that capecitabine maintenance after radiofrequency ablation significantly increased 5-year overall survival and reduced 5-year local tumor progression rates compared with radiofrequency ablation alone. This synergistic approach proactively targets micrometastatic disease. Despite the retrospective nature of the study, its robust results support the confirmation of systemic maintenance with local ablation in prospective randomized controlled trials.
